
Pivot Point Consulting Emerges as a Unified Healthcare IT Powerhouse Following Its Acquisition by Innovative Consulting Group

Three SV-created biotech companies included in The Times’ ‘100 Tech Ones to Watch’
Read More

FDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis

HPS/PayMedix Secures $33 Million Investment

CSA Medical Submits PMA for RejuvenAir® System Following Positive Results from Pivotal SPRAY-CB Trial

Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
SV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2

Packaging Compliance Labs Completes Acquisition of Quest Engineering Solutions, Expands Testing Capabilities and East Coast Presence

SUN Behavioral Health Acquires Seaside’s Community Agencies, Expanding Access to Community-Based Mental Health Services Across the Southeast

Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2

Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
27 September 2019Misonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys Medical
27 September 2019DDF notes Ribometrix raises $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform with Investment from DDF- 24 September 2019Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States
9 September 2019SV NewsDDF notes the appointment of Christian Jung, PhD as Partner- 27 August 2019PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
- 13 August 2019Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
12 August 2019DDF notes AstronauTx secures £6.5 million Financing with Investment from DDF
8 August 2019Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia
7 August 2019Q&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.
22 July 2019Washington Regional and Urgent Team Family of Urgent Care Join Forces- 17 July 2019Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer
8 July 2019DDF notes MedaRed Raises $6.5 Million Financing with Investment from DDF
